U.S. stocks closed lower on the last day of trade for August as investors digested a volatile month amid uncertainty about China and the Fed.» Read More
Shares of Merck and Schering-Plough are both under the weather Monday after a study said their Vytorin cholesterol drug isn't any better than a generic. Who wins and who loses?
Celebrex risky in high-risk heart patients, study finds
Stocks advanced Monday, led by financials, as the market looked for insight into the second quarter and braced for closing its worst quarter in 5 1/2 years.
Who’s the winner and loser in drug stocks today? Schering-Plough down 25 percent (!) and Merck down 16 percent pre-open on a study that showed that the companies cholesterol lowering drugs Vytorin and Zetia were not more effective than less expensive drugs.
Shares of Schering-Plough and Merck tumbled on Monday after doctors at a prominent medical meeting recommended patients try older cholesterol drugs before the companies' newer medicines.
Stocks opened mixed Monday as the market was on track for its worst quarter in 5 1/2 years and investors looked for insight into the second quarter.
AstraZeneca is stopping a clinical trial of its blockbuster cholesterol fighter Crestor early because of the clear benefits of the medicine compared to placebo, the company said on Monday.
In theory, Treasury Secretary Paulson's announcement that he wants to shake up the regulatory environment on Wall Street is the main news.
Yoda made an appearance at the American College of Cardiology (ACC) conference here in Chicago on Sunday. At the end of his speech in the opening session, the outgoing president of the organization played a "Star Wars" clip with the sage saying, "Try not. Do or do not. There is no try." He was trying to make a point about the ACC's role in forging healthcare reform.
In the absence of evidence that the cholesterol fighter Vytorin works better than a cheaper drug known as a statin, patients should turn back to using statins and other proven drugs, an expert panel said on Sunday.
U.S. researchers said on Friday they plan to expand the size of a major study to determine the heart benefits of the controversial cholesterol fighter Vytorin, which they said would delay results until 2012.
I don't know how I missed this one, but the Wall Street Journal's Health Blog didn't forget that this week that Pfizer and, perhaps, some men and women are celebrating the tenth birthday of Viagra. So, happy birthday little blue pill.
Ahead of the weekend, CNBC asks the experts where investors should place their bets.
The pharmaceutical sector faces the looming "patent cliff" -- but Credit Suisse's Catherine Arnold finds lots of opportunities in the sector for the careful investor.
Stocks retreated Thursday after another analyst warning on the financial sector and disappointing earnings from Oracle.
U.S. regulators on Thursday said they are probing a possible connection between Merck's Singulair asthma drug and suicidal behavior.
As proxy statements pop up on www.sec.gov, investors can get a peek at who's making what. When you go to the web site, click on "Search for company filings," then click on "Companies and other filers," enter the ticker symbol, click on "Find companies" and then open up the "14A" or proxy statement.
These days there's been a lot of media attention paid to the Merck and Schering-Plough partnership on the cholesterol-fighting drugs Zetia and Vytorin. But there's another less-known and little-talked-about respiratory MRK/SGP joint venture.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Stocks declined Wednesday amid profit-taking from the prior session's rally, a sharp drop in crude prices and lingering concerns about credit.